G

ood morning, everyone, and how are you today? We are just fine, thank you, especially with a warm and shiny sun beating down on the oh-so-quiet Pharmalot campus. Our short person has long since departed for the local schoolhouse and our official mascots are quietly snoozing in their cozy corners. As for us, yes, we are quaffing cups of stimulation — our choice today is flavored courtesy of the folks at Jack Daniels — and, as always, we invite you to join us. Remember, no prescription is required. Meanwhile, here are some tidbits. Hope you have a productive day …

Retail prescription drug spending slowed in 2016, increasing 1.3 percent to $328.6 billion, according to the Center for Medicare & Medicaid Services. The slower growth follows significant growth in 2014 and 2015, 12.4 percent and 8.9 percent, respectively, which was largely due to increased spending on new medicines and price growth for existing brand-name drugs, such as hepatitis C. Growth slowed due to fewer new drug approvals, slower growth in brand-name drug spending — such as for hepatitis C drugs — and less spending for generics as price growth slowed.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to Observer079 Cancel reply

Please enter your name.
Please enter a comment.

  • One may observe that ‘warm and shiny sun’ is in the eye of the beholder. If instead of viewing from Pharmalot central, our scribe had ventured forth for printed news matter, he would have found that shiny sun presiding over cold, 0 degrees C weather, though of course things will change …. they always do.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.